Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03610802 · ClinicalTrials.gov registry record
Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies
A clinical trial of Primary Immunodeficiency, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 3
- Study locations
NCT03610802 is a study of Primary Immunodeficiency that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 3,000 participants, below the 5,090-participant average among 4 other Primary Immunodeficiency trials with a reported enrollment target (41% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT03610802, a study of Primary Immunodeficiency, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 3
- Study locations
Study Summary
Background: The immune system helps the body fight infections. Primary immunodeficiency disorders (PIDs) are diseases that make it easier for people to get sick. Many PIDs are inherited. This means parents can pass them on to their children. Knowing what causes a person s PID is important to decide what treatment to give them. Objective: To test samples from people with a PID or people related to someone with a PID to find out what causes PIDs. Eligibility: People ages 99 or younger who have a PID or have a relative with a PID Design: Participants will be screened with a medical history over the phone. They may need to give permission for researchers talk to their doctors about their health. Their relatives may be contacted to see if they want to join the study. Participants will give samples. These could be: Blood: Participants blood will be taken from a vein in an arm, or with a prick on the finger or heel for children. Saliva, urine, or stool: Participants will provide each sample in a special cup. Nose or cheek swab: Participants will rub the skin inside their nose or cheek using a cotton swab. Cord blood: If participants have a baby during the study, blood will be collected from the baby s umbilical cord after it is born. Samples from medical procedures: If, during the study, the participants have a medical procedure that collects samples, the samples may be used for the study.
Conditions Studied
Study Locations (3)
Other
- Pavia Hospital (PH) - Pavia
- Marmara University Hospital, Istanbul Jeffrey Modell Diagnostic and Research Cen - Istanbul
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2038-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03610802
The ClinicalTrials.gov registry entry for NCT03610802 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,090-participant average among 4 other Primary Immunodeficiency trials with a reported enrollment target (41% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Immunodeficiency appearing as the primary indexed condition, and to 0 interventions.
NCT03610802 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, Maryland.
Frequently Asked Questions
What is clinical trial NCT03610802 about?
NCT03610802 is a clinical study titled "Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies". Background: The immune system helps the body fight infections. Primary immunodeficiency disorders (PIDs) are diseases that make it easier for people to get sick. Many PIDs are inherited. This means parents can pass them on to their children. Knowing what causes a person s PID is important to decide...
What is the current status of trial NCT03610802?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2019-07-22. Estimated completion is 2038-03-31.
What conditions does trial NCT03610802 study?
This clinical trial studies the following conditions: Primary Immunodeficiency.
Who is sponsoring clinical trial NCT03610802?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03610802 being conducted?
This trial has 3 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Immunodeficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
-
An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)
RECRUITING · Phase 4
-
NIAID Centralized Sequencing Protocol
RECRUITING
-
Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.